Karsten Kleo

Karsten Kleo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
NPNicole Pfarr
Nicole Pfarr
KSKarin von Schwarzenberg
Karin von Schwarzenberg
DZDario Zocholl
Dario Zocholl
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
JSJanna Siemanowski
Janna Siemanowski
OCon behalf of the German HRD assay Harmonization Consortium
on behalf of the German HRD assay Harmonization Consortium
PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency (HRD). The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, genomic instability (GI), and BRCA1/ 2 mutation status. Many of these assays have high potential to be broadly applied in clinical routine diagnostics in a time-effective decentralized manner. Here, we compare the performance of a multitude of alternative assays in comparison with Myriad myChoice in high-grade serous ovarian cancer (HGSOC). METHODS: DNA from HGSOC samples was extracted from formalin-fixed paraffin-embedded tissue blocks of cases previously run with the Myriad myChoice assay, and GI was measured by multiple molecular assays (CytoSNP, AmoyDx, Illumina TSO500 HRD, OncoScan, NOGGO GISv1, QIAseq HRD Panel and whole genome sequencing), applying different bioinformatics algorithms. RESULTS: Application of different assays to assess GI, including Myriad myChoice, revealed high concordance of the generated scores ranging from very substantial to nearly perfect fit, depending on the assay and bioinformatics pipelines applied. Interlaboratory comparison of assays also showed high concordance of GI scores. CONCLUSION: Assays for GI assessment not only show a high concordance with each other but also in correlation with Myriad myChoice. Thus, almost all of the assays included here can be used effectively to assess HRD-associated GI in the clinical setting. This is important as PARPi treatment on the basis of these tests is compliant with European Medicines Agency approvals, which are methodologically not test-bound.

5 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KKKarsten Kleo
Karsten Kleo
LDLora Dimitrova
Lora Dimitrova
EOElisabeth Oker
Elisabeth Oker
NTNancy Tomaszewski
Nancy Tomaszewski
EBErika Berg
Erika Berg
MHMichael Hummel
Michael Hummel
MYC is a heterogeneously expressed transcription factor that plays a multifunctional role in many biological processes such as cell proliferation and differentiation. It is also associated with many types of cancer including the malignant lymphomas. There are two types of aggressive B-cell lymphoma, namely Burkitt lymphoma (BL) and a subgroup of diffuse large cell lymphoma (DLBCL), which both carry MYC translocations and overexpress MYC but both differ significantly in their clinical outcome. In DLBCL, MYC translocations are associated with an aggressive behavior and poor outcome, whereas MYC-positive BL show a superior outcome. To shed light on this phenomenon, we investigated the different modes of actions of MYC in aggressive B-cell lymphoma cell lines subdivided into three groups: (i) MYC-positive BL, (ii) DLBCL with MYC translocation (DLBCLpos) and (iii) DLBCL without MYC translocation (DLBCLneg) for control. In order to identify genome-wide MYC-DNA binding sites a chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) was performed. In addition, ChIP-Seq for H3K4me3 was used for determination of genomic regions accessible for transcriptional activity. These data were supplemented with gene expression data derived from RNA-Seq. Bioinformatics integration of all data sets revealed different MYC-binding patterns and transcriptional profiles in MYC-positive BL and DLBCL cell lines indicating different functional roles of MYC for gene regulation in aggressive B-cell lymphomas. Based on this multi-omics analysis we identified ADGRE5 (alias CD97) - a member of the EGF-TM7 subfamily of adhesion G protein-coupled receptors - as a MYC target gene, which is specifically expressed in BL but not in DLBCL regardless of MYC translocation. Our study describes a diverse genome-wide MYC-DNA binding pattern in BL and DLBCL cell lines with and without MYC translocations. Furthermore, we identified ADREG5 as a MYC target gene able to discriminate between BL and DLBCL irrespectively of the presence of MYC breaks in DLBCL. Since ADGRE5 plays an important role in tumor cell formation, metastasis and invasion, it might also be instrumental to better understand the different pathobiology of BL and DLBCL and help to explain discrepant clinical characteristics of BL and DLBCL.

2 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AMArtuer Manukyan
Artuer Manukyan
KPKristin Peters
Kristin Peters
HRHelena Radbruch
Helena Radbruch
FFFederico Fusco
Federico Fusco
FGFelicitas Geserick
Felicitas Geserick
TRTorben Redmer
Torben Redmer
Summary: The cellular composition of the tumor ecosystem is a critical determinant of therapeutic responsiveness to immune checkpoint inhibitors (ICi) and BRAF inhibitors (BRAFi). However, the specific compositional dynamics that drive the subsequent progression of melanoma brain metastases (MBMs) remain poorly understood. Here, we performed single cell-resolved spatial transcriptomics profiling of multiple tissue cores (n=47) of distinct solitary and concordant multiple MBM (n=8), CNS tissue (n=7) and whole sections including one matched primary (n=4) of MBMs across various developmental stages and therapeutic regimens. Our approach uncovered both shared and distinct evolutionary patterns of MBM progression, revealing pronounced cellular and spatial heterogeneity, and identifying key tumor subsets characterized by MET or NGFR expression. Notably, spatial profiling of tumors progressing under ICi or BRAFi therapy identified a population of BZW2 + tumor cells that promotes an immunosuppressive microenvironment, thereby impeding immune cell infiltration and intratumoral dispersion. Elevated BZW2 expression was associated with ICi resistance and inversely correlated with the antigen transporter TAP1 and the activation of interferon/STAT1 signaling. Spatially aware automated profiling of immune-enriched niches distinguished “hot” niches—characterized by tumor expression of TAP1, PD-L2 and HLA-DRA—from “cold” zones, which were characterized by high levels of BZW2 and the transcriptional regulator SOX4. This translational suppressor co-localized with the clinically targetable MET receptor in a subset of tumor cells exhibiting distinct immune evasion features. Finally, multiplex imaging based on MACSima showed that, across all tumors, only 0.1% of CD8A + T cells were in an activated state. In summary, we provide insights into the single-cell and spatially resolved landscapes of MBM, identifying BZW2/SOX4 and TAP1 as potential determinants of ICi response.

17 June 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
SHStefan Habringer
Stefan Habringer
JIJana Ihlow
Jana Ihlow
KKKarsten Kleo
Karsten Kleo
AKAnna Klostermann
Anna Klostermann
MSMax Schmidt
Max Schmidt
DRDamian Rieke
Damian Rieke
A patient with gastrointestinal stroma tumor (GIST) and KIT p.V559D and BRAF p.G469A alterations was referred to our institutional molecular tumor board (MTB) to discuss therapeutic implications. The patient had been diagnosed with B-cell chronic lymphocytic leukemia (CLL) years prior to the MTB presentation. GIST had been diagnosed 1 month earlier. After structured clinical annotation of the molecular alterations and interdisciplinary discussion, we considered BRAF/KIT co-mutation unlikely in a treatment-naïve GIST. Discordant variant allele frequencies furthermore suggested a second malignancy. NGS of a CLL sample revealed the identical class 2 BRAF alteration, thus supporting admixture of CLL cells in the paragastric mass, leading to the detection of 2 alterations. Following the MTB recommendation, the patient received imatinib and had a radiographic response. Structured annotation and interdisciplinary discussion in specialized tumor boards facilitate the clinical management of complex molecular findings. Coexisting malignancies and clonal hematopoiesis warrant consideration in case of complex and uncommon molecular findings.

3 January 2024 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
DRDamian Rieke
Damian Rieke
LSLaura Katharina Schmalbrock
Laura Katharina Schmalbrock
JIJana Ihlow
Jana Ihlow
KKKarsten Kleo
Karsten Kleo
ABAnn-Christin von Brünneck
Ann-Christin von Brünneck
SOSebastian Ochsenreither
Sebastian Ochsenreither
Systemic mastocytosis is defined by the clonal proliferation of abnormal mast cells. The clinical course can range from indolent forms with normal life expectancy to advanced mast cell leukemia with dismal prognosis. An association with other diseases, including myeloproliferative neoplasia, has been described. We present a case of a 75-year patient with a history of cutaneous mastocytosis who was diagnosed with mast cell leukemia more than 9years ago and did not receive treatment. The patient presented to our clinic with acute kidney failure because of renal extramedullary hematopoiesis. Bone marrow histopathology revealed extensive fibrosis and 50 infiltration by mast cells with a c-KIT D816V mutation. No mutations supporting primary myelofibrosis were identified. Treatment with midostaurin was started, and the patient was discharged after improvement of renal function. Here, we discuss diagnostic challenges between different forms of mast cell leukemia and overlaps with other hematological malignancies.

30 September 2024 in Journal of Molecular Pathology
Verified
Journal Article
Open access
PDF file
KFKatharina Dorothée Faißt
Katharina Dorothée Faißt
CHCora Husemann
Cora Husemann
KKKarsten Kleo
Karsten Kleo
MTMonika Twardziok
Monika Twardziok
MHMichael Hummel
Michael Hummel
Aggressive B-cell lymphoma encompasses Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), and, as per the 2016 WHO classification, high-grade B-cell lymphoma (HGBL) not otherwise specified (NOS) and HGBL double/triple hit (DH/TH). However, the diagnostic distinction of HGBL from BL and DLBCL is difficult by means of histology/immunostaining in a substantial number of patients. This study aimed to improve subtyping by the identification of molecular features of aggressive B-cell lymphomas, with a specific focus on HGBL. To this end, we performed a comprehensive gene expression and mutational pattern analysis as well as the detection of B-cell clonality of 34 cases diagnosed with BL (n = 4), DLBCL (n = 16), HGBL DH (n = 8), and HGBL NOS (n = 6). Three distinct molecular subgroups were identified based on gene expression, primarily influenced by MYC expression/translocation and cell proliferation. In HGBL, compared to BL, there was an upregulation of PRKAR2B and TERT. HGBL DH exhibited elevated expression of GAMT and SMIM14, while HGBL NOS showed increased expression of MIR155HG and LZTS1. Our gene mutation analysis revealed MYC, ARID1A, BCL2, KMT2D, and PIM1 as the most affected genes in B-cell lymphoma, with BCL2 and CREBBP predominant in HGBL DH, and MYC and PIM1 in HGBL NOS. Clonality analysis of immunoglobulin heavy and light chain rearrangements did not show distinguishable V- or J-usage between the diagnostic subgroups.